JP2023133432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023133432A5 JP2023133432A5 JP2023121862A JP2023121862A JP2023133432A5 JP 2023133432 A5 JP2023133432 A5 JP 2023133432A5 JP 2023121862 A JP2023121862 A JP 2023121862A JP 2023121862 A JP2023121862 A JP 2023121862A JP 2023133432 A5 JP2023133432 A5 JP 2023133432A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- hcvr
- lcvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413198P | 2016-10-26 | 2016-10-26 | |
| US62/413,198 | 2016-10-26 | ||
| PCT/US2017/058555 WO2018081437A1 (en) | 2016-10-26 | 2017-10-26 | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| JP2019522823A JP7374765B2 (ja) | 2016-10-26 | 2017-10-26 | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522823A Division JP7374765B2 (ja) | 2016-10-26 | 2017-10-26 | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023133432A JP2023133432A (ja) | 2023-09-22 |
| JP2023133432A5 true JP2023133432A5 (https=) | 2024-01-19 |
Family
ID=60570180
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522823A Active JP7374765B2 (ja) | 2016-10-26 | 2017-10-26 | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 |
| JP2023121862A Pending JP2023133432A (ja) | 2016-10-26 | 2023-07-26 | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522823A Active JP7374765B2 (ja) | 2016-10-26 | 2017-10-26 | 抗ｄｋｋ－１抗体を使用して癌を治療するためのバイオマーカーとしてのベータ－カテニンの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11267876B2 (https=) |
| EP (1) | EP3532099A1 (https=) |
| JP (2) | JP7374765B2 (https=) |
| KR (1) | KR102701695B1 (https=) |
| CN (1) | CN110114087A (https=) |
| AU (1) | AU2017347822B2 (https=) |
| BR (1) | BR112019008279A2 (https=) |
| CA (1) | CA3041325A1 (https=) |
| IL (1) | IL266199B2 (https=) |
| MA (1) | MA46673A (https=) |
| MX (1) | MX2019004940A (https=) |
| RU (1) | RU2019115946A (https=) |
| SG (1) | SG11201903602RA (https=) |
| WO (1) | WO2018081437A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041325A1 (en) | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CA3128526A1 (en) | 2019-02-01 | 2020-08-06 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof |
| CA3151228A1 (en) * | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Use of dkk-1 inhibitors for treating cancer |
| EP4061419A1 (en) * | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| WO2023143444A1 (zh) | 2022-01-28 | 2023-08-03 | 上海君实生物医药科技股份有限公司 | 抗dkk1抗体、其药物组合物及用途 |
| US20250222062A1 (en) * | 2022-03-24 | 2025-07-10 | The Translational Genomics Research Institute | Peptide inhibitors targeting the tbl1-beta-catenin complex |
| CN116350758B (zh) * | 2023-03-16 | 2024-08-06 | 郑州大学 | 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| CA2677356A1 (en) | 2007-02-08 | 2008-08-14 | Zhiqiang An | Antibodies specific for dkk-1 |
| WO2009028158A1 (en) | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| EP2427490A1 (en) | 2009-05-07 | 2012-03-14 | Novartis AG | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2012103787A1 (en) * | 2011-02-01 | 2012-08-09 | The University Of Hongkong | Use of anti-dkk1 monoclonal antibody for treatment of liver cancer |
| JP6465790B2 (ja) * | 2013-02-27 | 2019-02-06 | 第一三共株式会社 | Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法 |
| CA2931975A1 (en) | 2013-12-02 | 2015-06-11 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| CA3041325A1 (en) | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CA3151228A1 (en) | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Use of dkk-1 inhibitors for treating cancer |
| EP4061419A1 (en) | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| WO2023039249A1 (en) | 2021-09-10 | 2023-03-16 | Leap Therapeutics, Inc. | Combination therapy |
| IL318268A (en) | 2022-07-12 | 2025-03-01 | Leap Therapeutics Inc | Combined treatment |
-
2017
- 2017-10-26 CA CA3041325A patent/CA3041325A1/en active Pending
- 2017-10-26 MX MX2019004940A patent/MX2019004940A/es unknown
- 2017-10-26 JP JP2019522823A patent/JP7374765B2/ja active Active
- 2017-10-26 BR BR112019008279-4A patent/BR112019008279A2/pt active Search and Examination
- 2017-10-26 WO PCT/US2017/058555 patent/WO2018081437A1/en not_active Ceased
- 2017-10-26 CN CN201780071597.0A patent/CN110114087A/zh active Pending
- 2017-10-26 KR KR1020197014600A patent/KR102701695B1/ko active Active
- 2017-10-26 IL IL266199A patent/IL266199B2/en unknown
- 2017-10-26 MA MA046673A patent/MA46673A/fr unknown
- 2017-10-26 SG SG11201903602RA patent/SG11201903602RA/en unknown
- 2017-10-26 EP EP17808633.6A patent/EP3532099A1/en active Pending
- 2017-10-26 AU AU2017347822A patent/AU2017347822B2/en active Active
- 2017-10-26 US US16/345,191 patent/US11267876B2/en active Active
- 2017-10-26 RU RU2019115946A patent/RU2019115946A/ru unknown
-
2022
- 2022-01-28 US US17/587,708 patent/US12319730B2/en active Active
-
2023
- 2023-07-26 JP JP2023121862A patent/JP2023133432A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023133432A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| US9469688B2 (en) | Therapeutic DLL4 binding proteins | |
| JP5964249B2 (ja) | 治療用ｄｌｌ４結合タンパク質 | |
| JP2021524256A5 (https=) | ||
| RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
| JP2021524244A5 (https=) | ||
| JP2021513540A5 (https=) | ||
| RU2019115946A (ru) | Применение бета-катенина в качестве биомаркера для лечения форм рака с помощью антитела к dkk-1 | |
| JP2022502010A5 (https=) | ||
| JP2021527640A5 (https=) | ||
| JP2022509156A5 (https=) | ||
| JP2009532336A5 (https=) | ||
| JP2018506277A5 (https=) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2017535257A5 (https=) | ||
| ME02371B (me) | Sastojci i postupci za dijagnstikovanje i tretman raka | |
| JP2018510617A5 (https=) | ||
| JP2021510736A5 (https=) | ||
| JP2022533538A5 (https=) | ||
| JP2012532851A5 (https=) | ||
| JP2024511137A5 (https=) | ||
| JP2020522280A5 (https=) | ||
| JP2013508292A5 (https=) | ||
| JP2022516351A5 (https=) |